Huifeng Niu

机构：Qingdao University, Affiliated Hospital of Qingdao University · ORCID：0000-0003-2181-7530

发表论文 32 篇 · 总被引 1683 次 · h-index 17

代表论文

• Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial (2021 · Journal of Thoracic Oncology · 被引 385)
• Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses (2019 · Journal of Thoracic Oncology · 被引 150)
• Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation (2011 · Cancer Research · 被引 75)
• Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor (2019 · Science Advances · 被引 70)
• BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines (2012 · PLoS ONE · 被引 61)
• Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer (2015 · Frontiers in Oncology · 被引 54)